As positive as everything sounds with GENE it should be recognized that when they roll out BREVAGen in March it is highly unlikely that the test will generate the hundreds of millions of dollars many shareholders are hoping for. The reality is it could take some time before they start to actually make a dent within their target market and even by that point there are no guarantees. The reality of the BREVAGen test is its nothing more than the company identifying clinical risks and genetic risks that GENE considers significant. What they have developed is not something that is truly unique and groundbreaking but rather something that has been commended for its strong classification rate when compared against the other products on the market. Of course this means that if another company is able to design a more accurate or cheaper test then it could be financially devastating for BREVAGen. In the meantime GENE is becoming a trendy trade for investors and with that rollout coming in March the company could easily see another spike as any news that address cancer prevention and cancer treatment often gets heavy attention.